A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3411-3418

  Hu, Wendy W ^a   Long, Gwynn D ^a,b   Stockerl Goldstein, Keith E ^a   Johnston, Laura J ^a   Chao, Nelson J ^a,b   Negrin, Robert S ^a   Blume, Karl G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; THIOTEPA;

APHERESIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; PACLITAXEL; RECURRENCE; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0032710562     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hryniuk W. The importance of dose intensity on the outcome of chemotherapy. In: V. DeVita, S. Hellman, and S. Rosenberg (eds.), Importance Advances in Oncology, pp. 121-141. Philadelphia: JB Lippincott, 1988.
2. Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med., 330: 1253-1259, 1994.
3. Focan, C., Andrien, J. M., Closon, M. T., Dicato, M., Driesschaert, P., Focan-Henrard, D., Lemaire, M., Lobelle, J. P., Longree, L., and Ries, F. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J. Clin. Oncol., 11: 1253-1263, 1993.
4. Hortobagyi, G. N., Buzdar, A. U., Frye, D., Legha, S. S., Malik, R., Smith, T. L., Blumenschein, G. R., Yap, H. Y., and Rodriguez, V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J. Clin. Oncol., 5: 354-364, 1987.
5. Lamar, R. E., Greco, F. A., Johnson, D. H., Murphy, P. B., and Hainsworth, J. D. High-dose brief duration, multiagent chemotherapy for metastatic breast cancer. Cancer (Phila.), 73: 1842-1848, 1994.
6. Honkoop, A. H., Hoekman, K., Wagstaff, J., Boven, E., van Groeningen, C. J., Giaccone, G., Vermorken, J. B., and Pinedo, H. M. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann. Oncol., 7: 35-39, 1996.
7. Bastholt, L., Dalmark, M., Gjedde, S. B., Pfeiffer, P., Pedersen, D., Sandberg, E., Kjaer, M., Mouridsen, H. T., Rose, C., Nielsen, O. S., et al. Dose-response relationship of epirubicin in the treatment of post-menopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J. Clin. Oncol., 14: 1146-1155, 1996.
8. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI, 010) Study Group. Ann. Oncol., 8: 155-162, 1997.
9. Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Diitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol., 15: 1858-1869, 1997.
10. Bezwoda, W. R., Seymour, L., and Dansey, R. D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J. Clin. Oncol., 776: 860-868, 1995.
11. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J. Y., Harousseau, J. L., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med., 333: 1540-1545, 1995.
12. Altal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med., 335: 91-97, 1996.
13. Crown, J., Kritz, A., and Vahdat, L. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol., 11: 1144-1149, 1993.
14. Shea, T. C., Mason, J. R., Storniolo, A. M., Bissent, E., Breslin, M., Mullen, M., and Taetle, R. High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for delivering repeated cycles of dose-intensive therapy. Cancer Treat. Rev., 19 (Suppl. C): 11-20, 1993.
15. Crown, J., and Norton, L. Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Ann. Oncol., 6 (Suppl 4): 21-26, 1995.
16. von Schilling, C., and Hermann, F. Dose-intensified treatment of breast cancer: current results. J. Mol. Med., 73: 611-627, 1995.
17. Patrone, F., Ballestrero, A., Ferrando, F., Brema, F., Moraglio, L., Valbonesi, M., Basta, P., Ghio, R., Gobbi, M., and Sessarego, M. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J. Clin. Oncol., 13: 840-846, 1995.
18. Demetri, D. G. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer. Pharmacotherapy, 16: 94S-100S, 1996.
19. Shapiro, C. L., Ayash, L., Webb, I. J., Gelman, R., Keating, J., Williams, L., Demetri, G., Clark, P., Elias, A., Duggan, D., et al. Repetitive cycles of cyclophosphamide, thiotepa and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J. Clin. Oncol., 15: 674-683, 1997.
20. Long, G. D., Negrin, R. S., Hoyle, C. F., Kusnierz-Glaz, C. R., Schriber, J. F., Blume, K. G., and Chao, N. J. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer (Phila.), 76: 860-868, 1995.
21. Klumpp, T. R., Mangan, K. F., Goldberg, S. L., Pearlman, E. S., and Macdonald, J. S. Granulocyte colony-simulating factor accelerates neutrophil engraftment following peripheral blood stem-cell transplantation: a prospective, randomized trial. J. Clin. Oncol., 13: 1323-1327, 1995.
22. Gianni, A. M., Bregni, M., Siena, S., Brambilla, C., Di Nicola, M., Lombardi, F., Gandola, L., Tarella, C., Pileri, A., Ravagnani, F., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med., 336: 1290-1297, 1997.
23. Gianni, A. M., Bregni, M., Siena, S., Di Nicola, M., Orefice, S., Cusumano, F., Salvadori, B., Luina, A., Greco, M., Zucali, R., et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J. Clin. Oncol., 15: 2312-2321, 1997.
24. Hudis, C. Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide. Oncology, 11: 15-18, 1997.
25. Demirer, T., Buckner, C. D., Lilleby, K., Weaver, C., Longin, K., Appelbaum, F. R., and Bensinger, W. I. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. Cancer (Phila.), 74: 715-721, 1994.
26. Ayash, L. J., Elias, A., Schwartz, G., Whller, C., Ibrahim, J., Teicher, B. A., Reich, E., Warren, D., Lynch, C., Richardson, P., et al. Double-dose intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J. Clin. Oncol., 14: 2984-2992, 1996.
27. Hryniuk, W., Frei, E., and Wright, F. A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose intensity. J. Clin. Oncol., 16: 3137-3147, 1998.
28. Antman, K. H. Dose-intensive therapy in breast cancer. In: J. O. Armitage and K. H. Antman (eds.), High-Dose Cancer Therapy. Baltimore, MD: Williams and Wilkins, 701-718, 1992.
29. Schiffman, K. S., Bensinger, W. I., Appelbaum, F. R., Rowley, S., Lilleby, K., Clift, R. A., Weaver, C. H., Demirer, T., Sanders, J. E., Petersdorf, S., et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant., 17: 943-950, 1996.
30. Bowers, C., Adkins, D., Dunph, F., Harrison, B., LeMaister, C. F., and Spitzer, G. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant., 12: 525-530, 1993.
31. Spitzer, G., Adkins, D., Dunphy, F., Petruska, P., Spencer, V., and Velasquez, W. Design of preparative regimens for stem cell transplantation in breast cancer. Breast Cancer Res. Treat., 26 (Suppl.): S3-S9, 1993.
32. de Vries, E. G., Rodenhuis, S., Schouten, H. C., Hupperets, P. S., Dolsma, W. V., Lebesque, J. V., Blijham, G. H., Bontenbal, M., and Mulder, N. H. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Breast Cancer Res. Treat., 39: 307-313, 1996.
33. Vahdat, L. T., Papadopoulos, K., Balmaceda, C., McGovern, T., Dunleavy, J., Kaufman, E., Fung, B., Garrett, T., Savage, D., Tiersten, A., Ayello, J., Bagiella, E., Heitjan, D., Antman, K., and Hesdorffer, C. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin. Cancer Res., 4: 1689-1695, 1998.
34. Cagnoni, P. J., Shpall, E. J., Bearman, S. I., Matthes, S., Ross, M., Taffs, S., and Jones, R. B. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Semin. Oncol., 23 (6 Suppl 15): 43-48, 1996.
35. Anderson, K. C., Soiffer, R., DeLage, R., Takvorian, T., Freedman, A. S., Rabinowe, S. L., Nadler, L. M., Dear, K., Heflin, L., Mauch, P., et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood, 76: 235-244. 1990.
36. Garaventa, A., Rondelli, R., Castagnola, E., Locatelli, F., Dallorso, S., Porta, F., Uderzo, C., Rossetti, F., Miniero, R., Andolina, M., et al. Fatal pneumopathy in children after bone marrow transplantation-report from the Italian Registry. Italian Association of Pediatric Hematology-Oncology BMT Group. Bone Marrow Transplant., 16: 669-674, 1995.
37. Castagnola, E., Dini, G., Lanino, E., Tasso, L., Dallorso, S., Garaventa, A., Rossi, G. A., and Giacchino, R. Low CD4 lymphocyte count in a patient with P. carinii pneumonia after autologous bone marrow transplantation. Bone Marrow Transplant., 15: 977-978, 1995.
38. Byrd, J. C., Hargis, J. B., Rester, K. E., et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am. J. Hematol., 49: 135-142, 1995.
39. Kulke, M. H., and Vance, E. A. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin. Infect. Dis., 25: 215-218, 1997.
40. Meisenberg, B., and McKee, D. P. carinii pneumonia (PCP) following tandem cycles of high-dose chemotherapy and autologous PBPC support (letter). Bone Marrow Transplant., 18: 823, 1996.
41. Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K. E., Long, G. D., Chao, N. J., and Blume, K. G. Analysis of factors associated with outcome following high dose chemotherapy with hematopoietic cell support for patients with stage IV breast cancer. 20th Annual San Antonio Breast Cancer Symposium, 305a, 1997.
42. Bensinger, W., Schiffman, K. S., Kolmberg, L., Holmber, L., Appelbaum, F. R., Maziarz, R., Montgomery, P., Ellis, E., Rivkin, S., Weiden, P., Lilleby, K., et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant., 19: 1183-1189, 1997.
43. Ayash, L. J., Wheeler, C., Fairclough, D., Schwartz, G., Reich, E., Warren, D., Schnipper, L., Antman, K., Frei, E., III, and Elias, A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J. Clin. Oncol., 13: 2043-2049, 1995.
44. Antman, K. H., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., Freytes, C. O., Gale, R. P., Hillner, B. E., Holland, H. K., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol., 15: 1870-1879, 1997.